By Associate Professor Anthony Michael Joshua

Conference Abstracts

Lin FP-Y; Martin C; Kocbek S; Joshua AM; Dear RF-G; Lim E; Chantrill LA; Chin VT; Epstein RJ, 2017, 'Identifying determinants of quality of life in patients undergoing systemic therapy for solid tumors.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, Vol. 35, presented at 53rd Annual Clinical Science Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Symposium on Old Targets, New Drugs - Her2 and MET, IL, Chicago, 02 June 2017 - 07 June 2017, http://dx.doi.org/10.1200/JCO.2017.35.15_suppl.6596

Buckman RA; Berman HK; Sridhar SS; Joshua AM, 2010, 'How much do the side effects of chemotherapy matter? Patients' attitudes to side effects versus a potential loss of duration of remission', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, Vol. 28, http://dx.doi.org/10.1200/jco.2010.28.15_suppl.e19585

Preprints

Apostolov E; Roden DL; Holliday H; Cazet A; Harvey K; Zhang H; Wu SZ; van der Leij S; Selth LA; Bartonicek N; Al-Eryani G; He M; Lundeberg J; Reeves J; Kench JG; Potter AJ; Stricker P; Joshua AM; Horvath L; Swarbrick A, 2024, Profiling of epithelial functional states and fibroblast phenotypes in hormone therapy-naïve localised prostate cancer, http://dx.doi.org/10.1101/2024.10.23.619925

Choi WY; Sánchez C; Li JJ; Dinarvand M; Adomat H; Ghaffari M; Khoja L; Vafaee F; Joshua AM; Chi KN; Guns EST; Hosseini-Beheshti E, 2022, Extracellular vesicles from biological fluids as potential biomarkers for prostate cancer, http://dx.doi.org/10.21203/rs.3.rs-1948091/v1

Thavaneswaran S; Lin FP; Kansara M; Grady JP; Espinoza D; Joshua AM; Grimison P; Craft P; Cosman R; Lee C; Harwood K; Chinchen S; Corpuz T; Ballinger M; Sebastian L; Simes J; Thomas D, 2022, A signal-seeking Phase II trial of Durvalumab and Tremelimumab Focused on Advanced, Rare and Less Common Cancers, http://dx.doi.org/10.1101/2022.06.30.22277092

Thavaneswaran S; Sebastian L; Kansara M; Ballinger M; Espinoza D; Lin F; Lee C; Sjoquist K; Grady J; Cowley M; Joshua A; Qiu M; Oakes S; Simes J; Thomas D, 2021, A Signal-seeking Phase Iia Trial of Palbociclib in Advanced Cancers With Cell Cycle Pathway Alterations – A Substudy of the Molecular Screening and Therapeutics (Most) Program, http://dx.doi.org/10.21203/rs.3.rs-254137/v1

Peter MR; Bilenky M; Isserlin R; Bader GD; Shen SY; De Carvalho DD; Hansen AR; Hu P; Fleshner NE; Joshua AM; Hirst M; Bapat B, 2020, Dynamics of the cell-free DNA methylome of metastatic prostate cancer during androgen-targeting treatment, http://dx.doi.org/10.1101/2020.04.08.032565

Other

Pook D; Geynisman DM; Carles J; de Braud F; Joshua AM; Perez-Gracia JL; Pérez CL; Shin SJ; Fang B; Barve M; Maruzzo M; Bracarda S; Kim M; Kerloeguen Y; Gallo JD; Maund SL; Harris A; Huang K-C; Poon V; Sutaria DS; Gurney H, 2024, Data from A phase Ib, open-label study evaluating the safety and efficacy of ipatasertib plus rucaparib in patients with metastatic castration-resistant prostate cancer, http://dx.doi.org/10.1158/1078-0432.c.6762576

Pook D; Geynisman DM; Carles J; de Braud F; Joshua AM; Perez-Gracia JL; Pérez CL; Shin SJ; Fang B; Barve M; Maruzzo M; Bracarda S; Kim M; Kerloeguen Y; Gallo JD; Maund SL; Harris A; Huang K-C; Poon V; Sutaria DS; Gurney H, 2024, Data from A phase Ib, open-label study evaluating the safety and efficacy of ipatasertib plus rucaparib in patients with metastatic castration-resistant prostate cancer, http://dx.doi.org/10.1158/1078-0432.c.6762576.v3

Pook D; Geynisman DM; Carles J; de Braud F; Joshua AM; Perez-Gracia JL; Pérez CL; Shin SJ; Fang B; Barve M; Maruzzo M; Bracarda S; Kim M; Kerloeguen Y; Gallo JD; Maund SL; Harris A; Huang K-C; Poon V; Sutaria DS; Gurney H, 2024, Supplementary Data 1 from A phase Ib, open-label study evaluating the safety and efficacy of ipatasertib plus rucaparib in patients with metastatic castration-resistant prostate cancer, http://dx.doi.org/10.1158/1078-0432.27032359.v1

Pook D; Geynisman DM; Carles J; de Braud F; Joshua AM; Perez-Gracia JL; Pérez CL; Shin SJ; Fang B; Barve M; Maruzzo M; Bracarda S; Kim M; Kerloeguen Y; Gallo JD; Maund SL; Harris A; Huang K-C; Poon V; Sutaria DS; Gurney H, 2024, Supplementary Data 1 from A phase Ib, open-label study evaluating the safety and efficacy of ipatasertib plus rucaparib in patients with metastatic castration-resistant prostate cancer, http://dx.doi.org/10.1158/1078-0432.27032359

Wheatley DA; Berardi R; Climent Duran MA; Tomiak A; Greystoke AP; Joshua AM; Arkenau H-T; Géczi L; Corbacho JG; Paz-Ares LG; Hussain SA; Petruželka L; Delmonte A; Chappey C; Masters JC; Michelon E; Murphy DA; Mwewa S; Cesari R; Doger de Spéville B, 2024, Data from First-line Avelumab plus Chemotherapy in Patients with Advanced Solid Tumors: Results from the Phase Ib/II JAVELIN Chemotherapy Medley Study, http://dx.doi.org/10.1158/2767-9764.c.7307352

Wheatley DA; Berardi R; Climent Duran MA; Tomiak A; Greystoke AP; Joshua AM; Arkenau H-T; Géczi L; Corbacho JG; Paz-Ares LG; Hussain SA; Petruželka L; Delmonte A; Chappey C; Masters JC; Michelon E; Murphy DA; Mwewa S; Cesari R; Doger de Spéville B, 2024, Data from First-line Avelumab plus Chemotherapy in Patients with Advanced Solid Tumors: Results from the Phase Ib/II JAVELIN Chemotherapy Medley Study, http://dx.doi.org/10.1158/2767-9764.c.7307352.v1

Wheatley DA; Berardi R; Climent Duran MA; Tomiak A; Greystoke AP; Joshua AM; Arkenau H-T; Géczi L; Corbacho JG; Paz-Ares LG; Hussain SA; Petruželka L; Delmonte A; Chappey C; Masters JC; Michelon E; Murphy DA; Mwewa S; Cesari R; Doger de Spéville B, 2024, FIGURE 1 from First-line Avelumab plus Chemotherapy in Patients with Advanced Solid Tumors: Results from the Phase Ib/II JAVELIN Chemotherapy Medley Study, http://dx.doi.org/10.1158/2767-9764.26125410

Wheatley DA; Berardi R; Climent Duran MA; Tomiak A; Greystoke AP; Joshua AM; Arkenau H-T; Géczi L; Corbacho JG; Paz-Ares LG; Hussain SA; Petruželka L; Delmonte A; Chappey C; Masters JC; Michelon E; Murphy DA; Mwewa S; Cesari R; Doger de Spéville B, 2024, FIGURE 1 from First-line Avelumab plus Chemotherapy in Patients with Advanced Solid Tumors: Results from the Phase Ib/II JAVELIN Chemotherapy Medley Study, http://dx.doi.org/10.1158/2767-9764.26125410.v1

Wheatley DA; Berardi R; Climent Duran MA; Tomiak A; Greystoke AP; Joshua AM; Arkenau H-T; Géczi L; Corbacho JG; Paz-Ares LG; Hussain SA; Petruželka L; Delmonte A; Chappey C; Masters JC; Michelon E; Murphy DA; Mwewa S; Cesari R; Doger de Spéville B, 2024, FIGURE 2 from First-line Avelumab plus Chemotherapy in Patients with Advanced Solid Tumors: Results from the Phase Ib/II JAVELIN Chemotherapy Medley Study, http://dx.doi.org/10.1158/2767-9764.26125407

Wheatley DA; Berardi R; Climent Duran MA; Tomiak A; Greystoke AP; Joshua AM; Arkenau H-T; Géczi L; Corbacho JG; Paz-Ares LG; Hussain SA; Petruželka L; Delmonte A; Chappey C; Masters JC; Michelon E; Murphy DA; Mwewa S; Cesari R; Doger de Spéville B, 2024, FIGURE 2 from First-line Avelumab plus Chemotherapy in Patients with Advanced Solid Tumors: Results from the Phase Ib/II JAVELIN Chemotherapy Medley Study, http://dx.doi.org/10.1158/2767-9764.26125407.v1

Wheatley DA; Berardi R; Climent Duran MA; Tomiak A; Greystoke AP; Joshua AM; Arkenau H-T; Géczi L; Corbacho JG; Paz-Ares LG; Hussain SA; Petruželka L; Delmonte A; Chappey C; Masters JC; Michelon E; Murphy DA; Mwewa S; Cesari R; Doger de Spéville B, 2024, Supplementary Data from First-line Avelumab plus Chemotherapy in Patients with Advanced Solid Tumors: Results from the Phase Ib/II JAVELIN Chemotherapy Medley Study, http://dx.doi.org/10.1158/2767-9764.26125401

Wheatley DA; Berardi R; Climent Duran MA; Tomiak A; Greystoke AP; Joshua AM; Arkenau H-T; Géczi L; Corbacho JG; Paz-Ares LG; Hussain SA; Petruželka L; Delmonte A; Chappey C; Masters JC; Michelon E; Murphy DA; Mwewa S; Cesari R; Doger de Spéville B, 2024, Supplementary Data from First-line Avelumab plus Chemotherapy in Patients with Advanced Solid Tumors: Results from the Phase Ib/II JAVELIN Chemotherapy Medley Study, http://dx.doi.org/10.1158/2767-9764.26125395.v1

Wheatley DA; Berardi R; Climent Duran MA; Tomiak A; Greystoke AP; Joshua AM; Arkenau H-T; Géczi L; Corbacho JG; Paz-Ares LG; Hussain SA; Petruželka L; Delmonte A; Chappey C; Masters JC; Michelon E; Murphy DA; Mwewa S; Cesari R; Doger de Spéville B, 2024, Supplementary Data from First-line Avelumab plus Chemotherapy in Patients with Advanced Solid Tumors: Results from the Phase Ib/II JAVELIN Chemotherapy Medley Study, http://dx.doi.org/10.1158/2767-9764.26125392.v1

Wheatley DA; Berardi R; Climent Duran MA; Tomiak A; Greystoke AP; Joshua AM; Arkenau H-T; Géczi L; Corbacho JG; Paz-Ares LG; Hussain SA; Petruželka L; Delmonte A; Chappey C; Masters JC; Michelon E; Murphy DA; Mwewa S; Cesari R; Doger de Spéville B, 2024, Supplementary Data from First-line Avelumab plus Chemotherapy in Patients with Advanced Solid Tumors: Results from the Phase Ib/II JAVELIN Chemotherapy Medley Study, http://dx.doi.org/10.1158/2767-9764.26125395

Wheatley DA; Berardi R; Climent Duran MA; Tomiak A; Greystoke AP; Joshua AM; Arkenau H-T; Géczi L; Corbacho JG; Paz-Ares LG; Hussain SA; Petruželka L; Delmonte A; Chappey C; Masters JC; Michelon E; Murphy DA; Mwewa S; Cesari R; Doger de Spéville B, 2024, Supplementary Data from First-line Avelumab plus Chemotherapy in Patients with Advanced Solid Tumors: Results from the Phase Ib/II JAVELIN Chemotherapy Medley Study, http://dx.doi.org/10.1158/2767-9764.26125398

Wheatley DA; Berardi R; Climent Duran MA; Tomiak A; Greystoke AP; Joshua AM; Arkenau H-T; Géczi L; Corbacho JG; Paz-Ares LG; Hussain SA; Petruželka L; Delmonte A; Chappey C; Masters JC; Michelon E; Murphy DA; Mwewa S; Cesari R; Doger de Spéville B, 2024, Supplementary Data from First-line Avelumab plus Chemotherapy in Patients with Advanced Solid Tumors: Results from the Phase Ib/II JAVELIN Chemotherapy Medley Study, http://dx.doi.org/10.1158/2767-9764.26125392

Wheatley DA; Berardi R; Climent Duran MA; Tomiak A; Greystoke AP; Joshua AM; Arkenau H-T; Géczi L; Corbacho JG; Paz-Ares LG; Hussain SA; Petruželka L; Delmonte A; Chappey C; Masters JC; Michelon E; Murphy DA; Mwewa S; Cesari R; Doger de Spéville B, 2024, Supplementary Data from First-line Avelumab plus Chemotherapy in Patients with Advanced Solid Tumors: Results from the Phase Ib/II JAVELIN Chemotherapy Medley Study, http://dx.doi.org/10.1158/2767-9764.26125401.v1

Wheatley DA; Berardi R; Climent Duran MA; Tomiak A; Greystoke AP; Joshua AM; Arkenau H-T; Géczi L; Corbacho JG; Paz-Ares LG; Hussain SA; Petruželka L; Delmonte A; Chappey C; Masters JC; Michelon E; Murphy DA; Mwewa S; Cesari R; Doger de Spéville B, 2024, Supplementary Data from First-line Avelumab plus Chemotherapy in Patients with Advanced Solid Tumors: Results from the Phase Ib/II JAVELIN Chemotherapy Medley Study, http://dx.doi.org/10.1158/2767-9764.26125404.v1

Wheatley DA; Berardi R; Climent Duran MA; Tomiak A; Greystoke AP; Joshua AM; Arkenau H-T; Géczi L; Corbacho JG; Paz-Ares LG; Hussain SA; Petruželka L; Delmonte A; Chappey C; Masters JC; Michelon E; Murphy DA; Mwewa S; Cesari R; Doger de Spéville B, 2024, Supplementary Data from First-line Avelumab plus Chemotherapy in Patients with Advanced Solid Tumors: Results from the Phase Ib/II JAVELIN Chemotherapy Medley Study, http://dx.doi.org/10.1158/2767-9764.26125398.v1

Wheatley DA; Berardi R; Climent Duran MA; Tomiak A; Greystoke AP; Joshua AM; Arkenau H-T; Géczi L; Corbacho JG; Paz-Ares LG; Hussain SA; Petruželka L; Delmonte A; Chappey C; Masters JC; Michelon E; Murphy DA; Mwewa S; Cesari R; Doger de Spéville B, 2024, Supplementary Data from First-line Avelumab plus Chemotherapy in Patients with Advanced Solid Tumors: Results from the Phase Ib/II JAVELIN Chemotherapy Medley Study, http://dx.doi.org/10.1158/2767-9764.26125404

Wheatley DA; Berardi R; Climent Duran MA; Tomiak A; Greystoke AP; Joshua AM; Arkenau H-T; Géczi L; Corbacho JG; Paz-Ares LG; Hussain SA; Petruželka L; Delmonte A; Chappey C; Masters JC; Michelon E; Murphy DA; Mwewa S; Cesari R; Doger de Spéville B, 2024, TABLE 1 from First-line Avelumab plus Chemotherapy in Patients with Advanced Solid Tumors: Results from the Phase Ib/II JAVELIN Chemotherapy Medley Study, http://dx.doi.org/10.1158/2767-9764.26125389.v1

Wheatley DA; Berardi R; Climent Duran MA; Tomiak A; Greystoke AP; Joshua AM; Arkenau H-T; Géczi L; Corbacho JG; Paz-Ares LG; Hussain SA; Petruželka L; Delmonte A; Chappey C; Masters JC; Michelon E; Murphy DA; Mwewa S; Cesari R; Doger de Spéville B, 2024, TABLE 1 from First-line Avelumab plus Chemotherapy in Patients with Advanced Solid Tumors: Results from the Phase Ib/II JAVELIN Chemotherapy Medley Study, http://dx.doi.org/10.1158/2767-9764.26125389

Wheatley DA; Berardi R; Climent Duran MA; Tomiak A; Greystoke AP; Joshua AM; Arkenau H-T; Géczi L; Corbacho JG; Paz-Ares LG; Hussain SA; Petruželka L; Delmonte A; Chappey C; Masters JC; Michelon E; Murphy DA; Mwewa S; Cesari R; Doger de Spéville B, 2024, TABLE 2 from First-line Avelumab plus Chemotherapy in Patients with Advanced Solid Tumors: Results from the Phase Ib/II JAVELIN Chemotherapy Medley Study, http://dx.doi.org/10.1158/2767-9764.26125386

Wheatley DA; Berardi R; Climent Duran MA; Tomiak A; Greystoke AP; Joshua AM; Arkenau H-T; Géczi L; Corbacho JG; Paz-Ares LG; Hussain SA; Petruželka L; Delmonte A; Chappey C; Masters JC; Michelon E; Murphy DA; Mwewa S; Cesari R; Doger de Spéville B, 2024, TABLE 2 from First-line Avelumab plus Chemotherapy in Patients with Advanced Solid Tumors: Results from the Phase Ib/II JAVELIN Chemotherapy Medley Study, http://dx.doi.org/10.1158/2767-9764.26125386.v1

Wheatley DA; Berardi R; Climent Duran MA; Tomiak A; Greystoke AP; Joshua AM; Arkenau H-T; Géczi L; Corbacho JG; Paz-Ares LG; Hussain SA; Petruželka L; Delmonte A; Chappey C; Masters JC; Michelon E; Murphy DA; Mwewa S; Cesari R; Doger de Spéville B, 2024, TABLE 3 from First-line Avelumab plus Chemotherapy in Patients with Advanced Solid Tumors: Results from the Phase Ib/II JAVELIN Chemotherapy Medley Study, http://dx.doi.org/10.1158/2767-9764.26125383.v1

Wheatley DA; Berardi R; Climent Duran MA; Tomiak A; Greystoke AP; Joshua AM; Arkenau H-T; Géczi L; Corbacho JG; Paz-Ares LG; Hussain SA; Petruželka L; Delmonte A; Chappey C; Masters JC; Michelon E; Murphy DA; Mwewa S; Cesari R; Doger de Spéville B, 2024, TABLE 3 from First-line Avelumab plus Chemotherapy in Patients with Advanced Solid Tumors: Results from the Phase Ib/II JAVELIN Chemotherapy Medley Study, http://dx.doi.org/10.1158/2767-9764.26125383

Pook D; Geynisman DM; Carles J; de Braud F; Joshua AM; Pérez-Gracia JL; Llácer Pérez C; Shin SJ; Fang B; Barve M; Maruzzo M; Bracarda S; Kim M; Kerloeguen Y; Gallo JD; Maund SL; Harris A; Huang K-C; Poon V; Sutaria DS; Gurney H, 2023, Data from A Phase Ib, Open-label Study Evaluating the Safety and Efficacy of Ipatasertib plus Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer, http://dx.doi.org/10.1158/1078-0432.c.6762576.v2

Pook D; Geynisman DM; Carles J; de Braud F; Joshua AM; Pérez-Gracia JL; Llácer Pérez C; Shin SJ; Fang B; Barve M; Maruzzo M; Bracarda S; Kim M; Kerloeguen Y; Gallo JD; Maund SL; Harris A; Huang K-C; Poon V; Sutaria DS; Gurney H, 2023, Supplementary Data 1 from A Phase Ib, Open-label Study Evaluating the Safety and Efficacy of Ipatasertib plus Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer, http://dx.doi.org/10.1158/1078-0432.24071513

Pook D; Geynisman DM; Carles J; de Braud F; Joshua AM; Pérez-Gracia JL; Llácer Pérez C; Shin SJ; Fang B; Barve M; Maruzzo M; Bracarda S; Kim M; Kerloeguen Y; Gallo JD; Maund SL; Harris A; Huang K-C; Poon V; Sutaria DS; Gurney H, 2023, Supplementary Data 1 from A Phase Ib, Open-label Study Evaluating the Safety and Efficacy of Ipatasertib plus Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer, http://dx.doi.org/10.1158/1078-0432.24071513.v1

Pook D; Geynisman DM; Carles J; de Braud F; Joshua AM; Pérez-Gracia JL; Llácer Pérez C; Shin SJ; Fang B; Barve M; Maruzzo M; Bracarda S; Kim M; Kerloeguen Y; Gallo JD; Maund SL; Harris A; Huang K-C; Poon V; Sutaria DS; Gurney H, 2023, Data from A Phase Ib, Open-label Study Evaluating the Safety and Efficacy of Ipatasertib plus Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer, http://dx.doi.org/10.1158/1078-0432.c.6762576.v1

Pook D; Geynisman DM; Carles J; de Braud F; Joshua AM; Pérez-Gracia JL; Llácer Pérez C; Shin SJ; Fang B; Barve M; Maruzzo M; Bracarda S; Kim M; Kerloeguen Y; Gallo JD; Maund SL; Harris A; Huang K-C; Poon V; Sutaria DS; Gurney H, 2023, Supplementary Data 1 from A Phase Ib, Open-label Study Evaluating the Safety and Efficacy of Ipatasertib plus Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer, http://dx.doi.org/10.1158/1078-0432.23791947

Pook D; Geynisman DM; Carles J; de Braud F; Joshua AM; Pérez-Gracia JL; Llácer Pérez C; Shin SJ; Fang B; Barve M; Maruzzo M; Bracarda S; Kim M; Kerloeguen Y; Gallo JD; Maund SL; Harris A; Huang K-C; Poon V; Sutaria DS; Gurney H, 2023, Supplementary Data 1 from A Phase Ib, Open-label Study Evaluating the Safety and Efficacy of Ipatasertib plus Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer, http://dx.doi.org/10.1158/1078-0432.23791947.v1

Back to profile page